louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00297557: Dual Time Point PET Imaging in Lymphoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hodgkin's or Non-Hodgkin's Lymphoma
Lead sponsor: Royal Marsden NHS Foundation Trust
Sponsor class: OTHER
First posted: 2006-02-28
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: Comparison of single time point with dual time point PET imaging in the accuracy of diagnosing active lymphoma. Biopsy results or clinical/radiological progression will be used in conjunction with the PET data.


Eligibility criteria: Inclusion Criteria:

- Age 16 and above Diagnosis of Hodgkin's or Non-Hodgkin's lymphoma PET scan scheduled as part of management

Exclusion Criteria:

* Pregnant or lactating Diabetes mellitus

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Royal Marsden NHS Foundation Trust
name: Dr Gary Cook
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00441857: Effect of Plant Stanols on Cholesterol Absorption
Official title: The Effect of Three Different Stanol Ester Doses in Margarines on Cholesterol Absorption Efficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypercholesterolemia
Keywords: plant sterols
plant stanols
cholesterol absorption
Lead sponsor: Oy Foodfiles Ltd
Sponsor class: OTHER
First posted: 2007-03-01
Enrollment: 60
Sex: ALL
Minimum age (years): 25
Maximum age (years): 68
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to measure the effect of three different doses of plant stanols in margarine on the cholesterol absorption efficiency in subjects with mildly to moderately increased serum LDL cholesterol concentrations

Detailed description: Serum cholesterol lowering effect of plant sterols is well established and it is also known that plant stanols inhibit the absorption of cholesterol. However, there is lack of dose-response studies directly measuring the cholesterol absorption efficiency during prolonged consumption of plant stanols. Therefore this study aims to measure the cholesterol absorption efficiency at different plant stanol consumption levels using a stable isotope tracer method.

Subjects will be randomized in their study groups that consume 20 g of margarine with different doses of plants stanols (0.8, 1.6 and 2.0g) based on cholesterol absorption efficiency at screening (high and low absorbers randomised separately). Cholesterol absorption test with cholesterol tracer will be conducted twice: at baseline and after 2-3 weeks margarine consumption period.

Cholesterol absorption efficiency will also be examined by indirect method i.e. by following the concentrations of serum cholesterol precursors and plant sterols in blood. In addition serum total, LDL and HDL cholesterol and triglycerides are followed.

Eligibility criteria: Inclusion Criteria:

* healthy adults with mild to moderate hypercholesterolemia

Exclusion Criteria:

* lipid lowering medication
* pregnancy or lactation
* severe diseases (inc. diabetes, unstable CVD, malignant diseases)
* severe obesity
* regular plant sterol consumption

Primary outcomes:
measure: cholesterol absorption efficiency
Secondary outcomes:
measure: changes in blood lipids
Other outcomes:
Locations:
city: Kuopio
country: Finland
facility: Oy Foodfiles Ltd
Study officials:
affiliation: Oy Foodfiles Ltd
name: Sakari A Nieminen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02632357: Longitudinal Experimental Study on ULNTT and Cervico-Thoracic Spine Motion Patterns Relationship
Official title: Longitudinal Experimental Study on ULNTT1 and Cervico-Thoracic Spine Motion Patterns Relationship
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervicobrachial Neuralgia
Keywords: Neurodynamics
Lead sponsor: University of Milano Bicocca
Sponsor class: OTHER
First posted: 2015-12-16
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Study Design: Longitudinal Experimental Study

Objective: Analyze the relationship between Upper Limb Neural Tension Test (ULNTT1) and cervico-thoracic spine biomechanics using a new motion-capture spine movement data analyzing model based on Least Square Approximation.

Summary of Background Data: ULNTT1 is a test able to determine cervical nerve roots and brachial plexus displacement within their interface structures. No studies were conducted about ULNTT1 and cervico-thoracic spine motion patterns relationship.

Methods: 12 subjects with ULNTT1 asymmetry \> 10° (AS group) and 11 subjects with ULNTT1 symmetry (S group) at clinical tests will be enrolled for the study. Subjects will be analyzed for ULNTT1 with an electrogoniometer using two parameters, one operator and one patient-dependent. Fine lateral bending cervico-thoracic spine motion patterns will be collected with motion-capturing technique and data will be analyzed with Least Square Approximation tools. Subjects with impairments in cervico-thoracic spine mobility will undergo to correction of those with spinal manipulative therapy. ULNTT1 and spine mobility will be so re-evaluated with same methods.


Eligibility criteria: Inclusion Criteria:

* AS group: ULNTT asymmetry \>10°
* S group: ULNTT symmetry

Exclusion Criteria:

* History of neck, shoulder or arm surgical interventions or major trauma, peripheral neuropathy, mental disturbance, limitation of shoulder, elbow or wrist range of motion, BMI \>25.

Primary outcomes:
measure: Upper Limb Neural Tension Test at baseline: R2
timeFrame: Baseline
measure: Upper Limb Neural Tension Test at baseline: P2
timeFrame: Baseline
measure: Cervico-Thoracic Spine Lateral Bending at baseline
timeFrame: Baseline
measure: Upper Limb Neural Tension Test after intervention: R2
timeFrame: Immediately after intervention, same day than baseline acquisition
measure: Upper Limb Neural Tension Test after intervention: P2
timeFrame: Immediately after intervention, same day than baseline acquisition
measure: Cervico-Thoracic Spine Lateral Bending after intervention
timeFrame: Immediately after intervention, same day than baseline acquisition
Secondary outcomes:
Other outcomes:
Locations:
city: Carate Brianza
country: Italy
facility: Istituti Clinici Zucchi
state: MB
Study officials:
References:
Clinical trial NCT01046357: A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687
Official title: A Randomized, Blind, Placebo-controlled, Single-centre Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD7687 After Single Ascending Oral Doses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: First in human
Safety
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2010-01-12
Enrollment: 64
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: This is a Phase I, first time in human, randomised, blinded, placebo-controlled, single ascending dose study in healthy male volunteers conducted at a single centre. The effect of food on the pharmacokinetics of AZD7687 will also be studied.

The study will consist of two parts, a dose escalation part and a food interaction part. The two parts will be run in parallel. In total, 64 healthy volunteers divided in 8 different panels (8 volunteers per cohort) will be exposed to single doses during the dose escalation. Each subject will receive dose only once, except for the volunteers included in the dose steps repeated for food interaction.


Eligibility criteria: Inclusion Criteria:

* Healthy
* BMI between 19-30

Exclusion Criteria:

* No blood donation prior 30 days
* No other clinical study prior 3 months

Primary outcomes:
measure: Safety variables (adverse events, vital signs, physical examination, telemetry, digital electrocardiograms (dECGs), safety 12-lead paper electrocardiograms (pECG), and clinical laboratory assessments)
Secondary outcomes:
measure: Plasma concentrations of AZD7687 and plasma pharmacokinetic parameters.
measure: Exploratory pharmacogenetic blood sampling.
measure: Pharmacodynamic biomarker sampling; blood samples.
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Research Site
state: Kansas
Study officials:
References:
Clinical trial NCT05570357: Berberine and Cinnamon in Management of Diabetes
Official title: The Effects of Berberine and Cinnamon Supplementation on Diabetes Mangement
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes
Keywords: Diabetes
Berberine
Cinnamon
Lead sponsor: National Nutrition and Food Technology Institute
Sponsor class: OTHER
First posted: 2022-10-06
Enrollment: 44
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this randomized clinical trial, patients with diabetes will be randomly assigned to receive either Berberine, and Cinnamon supplements or placebo for 12 weeks. Then the glycemic characteristics will be compared in two groups.


Eligibility criteria: Inclusion Criteria:

* Age 30-70 years
* Diagnosed type-2 diabetes mellitus (based on American Diabetes Association criteria)

Exclusion Criteria:

* Patients with an allergy to berberine /cinamon

  * Lactation, pregnancy
  * Patients with any malignancy
  * Patients with unrelated chronic illness
  * Patients with cardiac, liver or respiratory failure

Primary outcomes:
measure: HbA1C
timeFrame: 0 and 12th week
Secondary outcomes:
measure: Fasting blood sugar
timeFrame: 0 and 12th week
measure: Lipid profile
timeFrame: 0 and 12th week
measure: Anthropometric measurements
timeFrame: 0 and 12th week
measure: Blood Pressure
timeFrame: 0 and 12th week
measure: CRP
timeFrame: 0 and 12th week
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Azita Hekmatdoost
state: Middle East
Study officials:
References:
Clinical trial NCT02863757: Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease
Official title: Disease Progression and Clinical Outcomes in Chronic Hepatitis B (CHB) Patients With Comorbid Nonalcoholic Fatty Liver Disease (NAFLD)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Chronic Hepatitis B
Nonalcoholic Fatty Liver Disease
Lead sponsor: Humanity and Health Research Centre
Sponsor class: OTHER
First posted: 2016-08-11
Enrollment: 1500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Hosptials and primary care clinics

Brief summary: The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).


Eligibility criteria: Inclusion Criteria:

* Liver biopsy proved CHB and/or NAFLD at baseline;
* Chinese
* Follow-up duration\>12 months

Exclusion Criteria:

* Other liver diseases;
* Secondary causes of hepatic steatosis;
* Alcohol abuse;
* Liver cirrhosis, cirrhosis related complications or HCC at baseline;
* Malignancy;
* History of liver transplantation

Primary outcomes:
measure: Number of patients with liver cirrhosis, hepatic encephalopathy, esophageal varices, ascites and hepatocellular carcinoma
timeFrame: Up to 20 years
Secondary outcomes:
measure: Number of patients with hypertension, obesity, diabetes mellitus, hyperlipidaemia
timeFrame: Up to 20 years
measure: Number of patients with liver transplantation and liver-related death
timeFrame: Up to 20 years
measure: Diagnosis time of liver cirrhosis, hepatic encephalopathy, esophageal varices, ascites and hepatocellular carcinoma from baseline
timeFrame: Up to 20 years
measure: Occurrence time of liver transplantation and liver-related death from baseline
timeFrame: Up to 20 years
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Humanity and Health GI and Liver Centre
state: Hong Kong
Study officials:
References:
Clinical trial NCT06174857: Efficacy of Osimertinib in Patients With Lung Cancer
Official title: Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Advanced Non-Small Cell Lung Cancer
Lead sponsor: Hunan Province Tumor Hospital
Sponsor class: OTHER
First posted: 2023-12-18
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: advanced or metastatic (stage IV) lung cancer

Brief summary: This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.


Eligibility criteria: Inclusion Criteria:

* Patients must be ≥18 years.
* Provision of fully informed consent prior to any study specific procedures.
* Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology.
* According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.

Exclusion Criteria:

* None

Primary outcomes:
measure: progression-free survival
timeFrame: 3 years
measure: Overall survival
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Changsha
country: China
facility: Hunan Cancer hospital
state: Hunan
Study officials:
affiliation: Hunan Cancer Hospital
name: Yongchang Zhang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03776357: A Rehabilitation Tool to Determine Patient's Stay in Hospital After Joint Replacement
Official title: A Rehabilitation Tool to Determine Patient's Stay in Hospital After Joint Replacement
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Total Joint Replacement Surgery
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2018-12-14
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This is the research study of a rehabilitation tool that informs, guides and empowers clinicians to care for their patients. We hope to learn ways to improve patient outcomes, reduce costs and increase value to the healthcare system

Detailed description: The investigator hope to learn co-relation between the rehab tool and clinical findings and analyse association if any. Rehab tool will optimize care according to the patient's specific needs and provided insights to patients length of stay in the hospital. these data driven insights will be used to observe correlation between machine and clinic data

Eligibility criteria: Inclusion Criteria:

* Patient scheduled for Primary unilateral total joint replacement
* Patient age should be more than or equal to 18 years.
* Patient must speak English

Exclusion Criteria:

* Patients undergoing bilateral primary knee replacement surgery
* Patients undergoing revision knee replacement surgery
* No uncorrectable deformity
* No deformity greater than 15 degree
* No hip arthritis
* No wheelchair dependency
* Patients not willing and capable to sign the written informed consent

Primary outcomes:
measure: Length of Stay in Hospital Through Discharge
timeFrame: Up to 2 days
Secondary outcomes:
measure: Number of Participants Requiring Gait Aid Use
timeFrame: 3 months post operative visit
measure: Knee Society Score (KSS)
timeFrame: 3 months post operative visit
measure: Knee Range of Motion
timeFrame: 3 months post operative visit
Other outcomes:
Locations:
city: Redwood City
country: United States
facility: Stanford outpatient center
state: California
Study officials:
References:
Clinical trial NCT01711957: The Perioperative Value of Platelet Counts in Predicting Outcome After Liver Transplantation
Official title: The Perioperative Value of Platelet Counts in Predicting Outcome After Liver Transplantation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Complication
Death
Keywords: Complications
Mortality
Liver transplantation
Platelet count
Survival
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2012-10-23
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with end stage liver disease and/or primary liver tumor undergoing liver transplantation

Brief summary: Recent experimental and clinical studies have shown that platelets play a critical role in liver ischemia and regeneration. Thrombocytopenia, a frequent and potentially serious condition in liver transplantation (LT) recipients, was shown to be associated with postoperative morbidity and mortality after partial hepatectomy.

The investigators aim at evaluating whether postoperative low platelet counts are indicators of short- and long-term outcomes after liver transplantation.


Eligibility criteria: Inclusion Criteria:

* Age \>18 years old
* End stage liver disease
* Cadaveric-donor liver transplantation

Exclusion Criteria:

* Age \<18 years old
* Pregnancy
* Living-related liver transplantation

Primary outcomes:
measure: Severe complication after liver transplantation
timeFrame: 90 days
Secondary outcomes:
measure: Primary graft non-function
timeFrame: first postoperative week
measure: Delayed graft function
timeFrame: 7 days after liver transplantation
Other outcomes:
measure: Patient survival
timeFrame: 3-year
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Department of Visceral Surgery and Transplantation
Study officials:
affiliation: University of Zurich
name: Mickael Lesurtel, M.D., PhD
role: STUDY_DIRECTOR
affiliation: University of Zurich
name: Pierre-Alain Clavien, M.D., PhD
role: STUDY_CHAIR
affiliation: University of Zurich
name: Dimitri A. Raptis, M.D., MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Zurich
name: Emmanuel Melloul, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lesurtel M, Raptis DA, Melloul E, Schlegel A, Oberkofler C, El-Badry AM, Weber A, Mueller N, Dutkowski P, Clavien PA. Low platelet counts after liver transplantation predict early posttransplant survival: the 60-5 criterion. Liver Transpl. 2014 Feb;20(2):147-55. doi: 10.1002/lt.23759. Epub 2013 Nov 21.
Clinical trial NCT05579457: Physical Performance Levels and Social Participation in Elderly Living In Urban and Rural Areas
Official title: Effect of Physical Performance Levels of Elderly Living In Urban and Rural Areas on Social Participation, Social Functioning, and Quality of Life
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Eldrely
Lead sponsor: Suleyman Demirel University
Sponsor class: OTHER
First posted: 2022-10-13
Enrollment: 418
Sex: ALL
Minimum age (years): 65
Maximum age (years): 100
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: This study was carried out with the participation of elderly residing in the provinces of Isparta, Burdur, and Antalya in the Mediterranean region of Turkey

Brief summary: Purpose: This study aims to investigate the effect of physical performance levels of elderly living in rural and urban areas on social participation, social functioning, and quality of life.

Method: A total of 418 volunteer elderly aged 65 and over living in rural (42.3%) and urban (57.7%) areas participated in this study. The Mini-Mental State Examination, Short Physical Performance Battery, the World Health Organization Quality of Life Scale for Older Adults, Leisure Time subscale of the Social Functioning Scale and the Community Integration Questionnaire were applied to participants.


Eligibility criteria: Inclusion Criteria:

* individuals over the age of 65 years who received a score of ≥24 from the Mini-Mental State Examination were included in the study

Exclusion Criteria:

* elderly who were unable to communicate verbally, were unable to move independently, had undergone any operations in the last 6 months, had been diagnosed with cancer, or had severe vision loss, stroke, Parkinson's disease, multiple sclerosis, or other neurological diseases were excluded from the study

Primary outcomes:
measure: Community Integration Questionnaire
timeFrame: 02.04.2021
Secondary outcomes:
measure: Social Functioning Scale (
timeFrame: 02.04.2021
Other outcomes:
Locations:
city: Isparta
country: Turkey
facility: Tahir KESKİN
state: Merkez
Study officials:
References:
Clinical trial NCT00541957: Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients
Official title: Randomized Trial of Psychotherapy for Persistently Depressed Primary Care Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Major Depression
Keywords: Major depression
Primary care
Lead sponsor: Butler Hospital
Sponsor class: OTHER
Collaborators: name: Memorial Hospital of Rhode Island
First posted: 2007-10-10
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a pilot study. The purpose of this study is to determine whether adding 4 months of behavioral therapy to primary care physician medication treatment(relative to medication treatment alone) improves outcomes for persistently depressed primary care patients.


Eligibility criteria: Inclusion Criteria:

* Current MDD or MDD within the past year or current dysthymia
* PHQ-9 \> 10
* have been prescribed an antidepressant medication (by their PCP) at least 8 weeks before pre-treatment timepoint
* are able to speak, read, and understand English sufficiently well to complete study procedures
* are between the ages of 18 and 70

Exclusion Criteria:

* presence of significant suicidal ideation or risk
* history of bipolar disorder, schizophrenia, psychotic symptoms, or severe alcohol or drug problems within the past year;
* history of antisocial personality disorder or borderline personality disorder;
* currently in psychotherapy or have received counseling more frequently than once per month in the past year.

Primary outcomes:
measure: Depression symptoms
timeFrame: 4 months
Secondary outcomes:
measure: Psychosocial functioning
timeFrame: 4 months
Other outcomes:
Locations:
city: Pawtucket
country: United States
facility: Memorial Hospital of RI
state: Rhode Island
city: Providence
country: United States
facility: Butler Hospital
state: Rhode Island
Study officials:
affiliation: Butler Hospital
name: Lisa Uebelacker, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Uebelacker LA, German NM, Gaudiano BA, Miller IW. Patient health questionnaire depression scale as a suicide screening instrument in depressed primary care patients: a cross-sectional study. Prim Care Companion CNS Disord. 2011;13(1):PCC.10m01027. doi: 10.4088/PCC.10m01027.